Back to Test Catalogue

Prostate Specific Antigen (PSA) – Free and Total, Serum/Plasma

Test ID: FPSA
Orderable by Ontario ND
Test
Specimen
Performance / Interpretation
Interface / Setup

Test

Method

ECLIA

Report Includes

Total PSA; Free PSA; Free PSA/Total PSA Ratio

Specimens

Serum; Plasma (Li Heparin); Plasma (EDTA)

Test Version

1-Feb-2023

Specimen

Specimens

Serum; Plasma (Li Heparin); Plasma (EDTA)

Sample Volume

2 mL

Specimen Comment

Barricor™ tube is not acceptable.

Collection & Handling

Collection Instructions

Recommend collecting prior to rectal exam or other action that may alter circulating PSA concentration.

Handling Information

Store and send frozen.

Stability

Refrigerated 5 days
Frozen 3 months

Rejection Criteria

Specimen Barricor™ tube

Test Version

1-Feb-2023

Performance / Interpretation

Method

ECLIA

Turnaround Time

2 days

Results

Name Units Reference Range Conversion Factor
PSA - Total µg/L
  • Less than 4.0
  • May be increased by prostate manipulation (massage/biopsy) or cytoscopy. Hospitalization may decrease PSA levels.
 ng/mL x 1.00
Free PSA µg/L
  • See interpretation for Free/Total PSA Ratio.
 ng/mL x 1.00
Free PSA/Total PSA Ratio Ratio
  • Total <4: Prostate cancer unlikely and Free is not informative.
  • Total ≥10: Prostate cancer likely and Free is not informative.
  • Total ≥4 and ≤10: If Free/Total ratio ≥0.27, chance of prostate cancer is about 10%. If ratio is <0.17, chance of prostate cancer is about 50%.

Test Version

1-Feb-2023

Interface / Setup

HL7 Interface Codes

Order Code Result Codes Units
FPSA 20696Prostate Spec Ag (Monitor) ug/L
20697Free PSA (Monitor) ug/L
20698Free/Total PSA Ratio

Test Version

1-Feb-2023